Lubiprostone

Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397) -induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research[1][2][3].

Product Specifications

CAS Number

[136790-76-6]

Product Name Alternative

RU-0211; SPI-0211

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

CFTR; Chloride Channel; Glutathione Peroxidase; NO Synthase; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lubiprostone.html

Purity

99.09

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C(F)(F)CCCC)CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O

Molecular Formula

C20H32F2O5

Molecular Weight

390.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Ao M, et al., Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 2011 Feb;56 (2) :339-51.|[2]Kim MY, et al., Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice. Life Sci. 2022 Dec 15;311 (Pt A) :121176.|[3]Hayashi S, et al., Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. J Pharmacol Exp Ther. 2014 Jun;349 (3) :470-9.